Equity Overview
Price & Market Data
Price: $10.24
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $522,767,232
Daily Volume: 0
Performance Metrics
1 Week: 19.49%
1 Month: 20.75%
3 Months: 40.27%
6 Months: 19.77%
1 Year: 286.4%
YTD: 36.53%
Company Details
Employees: 196
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.